Therefore, we suggest that syndecan-1 levels should be evaluated in RA patients with moderate or severe disease activity in further studies to identify whether the levels of this molecule could be predictive of different outcomes in RA patients. The gene discussed is SDC1; the disease is rheumatoid arthritis.